Q4 2024 Inogen Inc Earnings Call Transcript
Key Points
- Inogen Inc (INGN) reported a 6.4% growth in full-year 2024 revenue, reaching over $335 million.
- The company achieved FDA clearance for the Simeox device, expanding its product portfolio.
- Inogen Inc (INGN) launched the Rove 4 POC, receiving positive feedback for its lightweight design and long battery life.
- A strategic collaboration with Yuwell Medical was established, providing a $27 million investment and expanding market reach in China.
- Significant improvements in gross margins were reported, with a 821 basis points increase in the fourth quarter of 2024.
- Direct-to-consumer (DTC) sales decreased by 21.3% in the fourth quarter due to a downsized sales force.
- Rental revenue declined by 16.5%, primarily due to lower average billing rates and a shift to private payers.
- Inogen Inc (INGN) reported a GAAP net loss of $9.8 million for the fourth quarter of 2024.
- The company anticipates a modest impact from the Yuwell collaboration on 2025 revenue, indicating a slow ramp-up.
- Challenges in the DTC channel are expected to continue into the first half of 2025 due to previous sales force reductions.
Welcome to Inogen's fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded today, February 25, 2025.
I would now like to turn the call over to Ryan Peterson, Investor Relations.
Thank you all for participating in today's call. Joining me are President and CEO, Kevin Smith; and CFO, Mike Bourque.
Earlier today, Inogen released financial results for the fourth-quarter and full-year 2024. The earnings release is available in the Investor Relations section of the company's website, along with the supplemental financial package. As a reminder, the information presented today will include forward-looking statements, including, without limitation, statements about our growth prospects and strategy for 2025 and beyond.
Expectations related to our financial results for the first-quarter and full-year 2025. Progress of our strategic initiatives including innovation, our expectations regarding the market for our products and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
